Drug Trial Radar · NCT00971152
Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle
Last checked: Nov 20, 2026Latest source record: Mar 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
366
Actual
Start
Sep 2009
Primary completion
Oct 2013
Study completion Feb 2014
Sponsor
- Lead sponsor
- Clinique OvoIndustry
- Sponsor type
- Industry
- Collaborators
- Ferring Pharmaceuticals
- First posted
- Sep 3, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily dose is administered for women who are at risk of a poor ovarian response in order to determine if one dose or the other results in improved cycle outcomes.
Conditions
- Subfertility
Interventions
menotropins for injectionDrug
comparison of different dosages
urofollitropin for injectionDrug
comparison of different dosages
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of metaphase II oocytes retrieved during the course of one treatment cycleTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ovo Fertilité
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.